1. Systemic Anti Cancer Therapy (SACT) Cancer 52 Ralphael Oghagbon

2. What is currently available and how do I gain access?
Nationally Area Team Hospital
Coverage Map
Numbers in Treatment
Top Regimens
Data Completeness
Benchmarking
Post Chemo Mortality

3. Coverage Map: A National Perspective

4. So… what do the numbers tell us?
February 14 to January ‘15
March 14 to February 15
Patients Receiving Drug Treatments
163,840
165,256
Regimens Commenced
278,354
282,646
Cycles Commenced
774,958
790,868
The figures listed above represent the number of patients reported to the CIU through SACT, for whom treatment activity has been submitted for the period covering August 2013 through July 2014 inclusive.

5. How good is the data nationally?
SACT data completeness, March 2014 to February 2015
Data completeness

6. How do less common cancers compare to other diagnostic groups

7. Can I find out how complete my hospital’s Rare Cancer data is?
There are reports available to download through the secure online SACT portal:
SACT Data Completeness Profile
One-page summary by diagnostic group with national comparison
SACT Data Quality Profile
One-page summary focused on recording of ‘Treatment Intent’ and ‘Cycle Start Date’ data items

8. Between July 2013 and June 2014, there were 1,709 patients reported to be receiving chemotherapy treatment for haematological malignancies (lymphoma, myeloma, leukaemia).

9. Top Regimens by Diagnostic Group Brain/CNS
ICD10: C47, C69-C72
All submitting trusts aggregated
Data received for October September Patients aged 16 and over
These reports are available at a provider level
There are in excess of 109 regimens for this disease group
Total patients recorded as receiving regimen is shown in parenthesis after regimen name
e.g. IMATINIB (265) = 3,959 patients receiving IMATINIB.
These patients received 1,503 cycles of IMATINIB between July 2013 – June 2014, with 145 being first cycles (starting treatment between July 2013 – June 2014).

10. Top Regimens by Diagnostic Group Sarcoma
ICD10: C40-C41, C46, C49 or various morphology codes
All submitting trusts aggregated
Data received for October September Patients aged 16 and over
These reports are available at a provider level
There are in excess of 165 regimens for this disease group
Total patients recorded as receiving regimen is shown in parenthesis after regimen name
e.g. IMATINIB (265) = 3,959 patients receiving IMATINIB.
These patients received 1,503 cycles of IMATINIB between July 2013 – June 2014, with 145 being first cycles (starting treatment between July 2013 – June 2014).

11. GIST- Gastrointestinal stromal Tumors

13. Top regimens reported for gastro-intestinal stromal tumours
Morphology: M8936
All submitting trusts aggregated
Data received for October September Patients aged 16 and over
*Curative group includes adjuvant and neo-adjuvant intent

14. Post Chemotherapy Mortality Analysis
From 25th July 2014 all NHS providers of chemotherapy in England have been able to access their 30/60/90-day post chemotherapy mortality analysis through the secure online portal.
This analysis is available by tumour group and will provide a national comparison.
It is essential that clinical teams within provider organisations check the accuracy of their data and contact the team in Oxford where there are any possible discrepancies.
A letter to Medical Directors and Lead Chemotherapy Consultants has been sent out raising awareness of these reports.

15. Post Chemotherapy Mortality Analysis (2)
For demonstration purposes only

16. Post Chemotherapy Survival Analysis Less Common Cancer all treatment intents
For demonstration purposes only
Red line = Trust survival curve
Blue line = All submitting trusts aggregated (i.e. National average)
Quality assurance is vital before post-chemotherapy survival analysis can be released into public domain.
Encourage all trusts to actively verify data submitted through SACT.

17. Cancer Drugs Fund (CDF) data
NHS England is responsible for delivery of the Cancer Drugs Fund
Public Health England commissioned to audit Cancer Drugs Fund
Expectation for Cancer Drugs Fund treatments to be reported through SACT by each hospital

18. Improving Stakeholder Engagement
Members of the CIU team will be attending the following meetings:
NHS England Area Team Pharmacist Meeting
NHS England Chemotherapy Clinical Reference Group
Chemotherapy Clinical Information Group
NCIN Site Specific Clinical Reference Groups (SSCRG)
e.g. CNS workshop, CTYA meeting
Would you like to know more about SACT? Please contact the team, we are always happy to discuss the project or meet with you.